Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon3 and 1 bp insertion in exon3.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IFI35, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IFI35 also known as Interferon-induced 35 kDa protein plays a role mechanically in the regulation of immune responses. It has a molecular mass of approximately 35 kDa. This protein is expressed in various tissues with high levels found in the liver lungs and spleen. IFI35 interacts with numerous proteins particularly within the cytoplasm to execute its functions.
Biological function summary
The protein modulates the innate immune system and interacts with other interferon-induced proteins. It forms a complex with NMI (N-Myc interactor) which stabilizes each other. Through these interactions IFI35 contributes to antiviral defense mechanisms and possibly acts in response to cellular stress.
Pathways
IFI35 engages in the interferon signaling pathway and the Jak-STAT pathway. These pathways play critical roles in mediating immune responses to viral infections. IFI35 works together with related proteins like STAT1 and NMI within these pathways providing a framework for antiviral activity and influence on cell survival.
IFI35 has associations with viral infections and autoimmune diseases. Viral pathogenesis can see modulation by IFI35 particularly infections caused by the hepatitis C virus. Furthermore its interaction with NMI may also play a part in autoimmune disorders by influencing inflammatory responses. These links highlight IFI35's significant contributions to disease mechanisms and therapeutic potential in managing immune-related conditions.
